Cargando…
Decade in review: a new era for RET-rearranged lung cancers
Targeted therapy has become the standard of care for non-small cell lung cancers with a range of targetable alterations, including ALK and ROS1 kinase fusions. RET fusions drive the oncogenesis of 1–2% of NSCLCs and represent a substantial global burden of disease. Although these fusions were first...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815364/ https://www.ncbi.nlm.nih.gov/pubmed/33489819 http://dx.doi.org/10.21037/tlcr-20-346 |
_version_ | 1783638214284673024 |
---|---|
author | Choudhury, Noura J. Drilon, Alexander |
author_facet | Choudhury, Noura J. Drilon, Alexander |
author_sort | Choudhury, Noura J. |
collection | PubMed |
description | Targeted therapy has become the standard of care for non-small cell lung cancers with a range of targetable alterations, including ALK and ROS1 kinase fusions. RET fusions drive the oncogenesis of 1–2% of NSCLCs and represent a substantial global burden of disease. Although these fusions were first identified more than thirty years ago, targeted therapy for RET fusion-positive lung cancers was only explored in the last decade. Whereas repurposed multikinase inhibitors were initially tested, selective inhibitors RET inhibitors have dramatically improved outcomes for patients whose tumors harbor these alterations. In 2020, the US Food and Drug Administration approved selpercatinib, a selective RET inhibitor, for adults with lung and thyroid cancers with RET rearrangements or mutations, making it the first targeted therapy to be approved for RET-altered cancers. While resistance to selective RET inhibition has been described, next-generation RET inhibitors are already being explored for patients who progress on prior RET kinase inhibitors. |
format | Online Article Text |
id | pubmed-7815364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-78153642021-01-22 Decade in review: a new era for RET-rearranged lung cancers Choudhury, Noura J. Drilon, Alexander Transl Lung Cancer Res Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions Targeted therapy has become the standard of care for non-small cell lung cancers with a range of targetable alterations, including ALK and ROS1 kinase fusions. RET fusions drive the oncogenesis of 1–2% of NSCLCs and represent a substantial global burden of disease. Although these fusions were first identified more than thirty years ago, targeted therapy for RET fusion-positive lung cancers was only explored in the last decade. Whereas repurposed multikinase inhibitors were initially tested, selective inhibitors RET inhibitors have dramatically improved outcomes for patients whose tumors harbor these alterations. In 2020, the US Food and Drug Administration approved selpercatinib, a selective RET inhibitor, for adults with lung and thyroid cancers with RET rearrangements or mutations, making it the first targeted therapy to be approved for RET-altered cancers. While resistance to selective RET inhibition has been described, next-generation RET inhibitors are already being explored for patients who progress on prior RET kinase inhibitors. AME Publishing Company 2020-12 /pmc/articles/PMC7815364/ /pubmed/33489819 http://dx.doi.org/10.21037/tlcr-20-346 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions Choudhury, Noura J. Drilon, Alexander Decade in review: a new era for RET-rearranged lung cancers |
title | Decade in review: a new era for RET-rearranged lung cancers |
title_full | Decade in review: a new era for RET-rearranged lung cancers |
title_fullStr | Decade in review: a new era for RET-rearranged lung cancers |
title_full_unstemmed | Decade in review: a new era for RET-rearranged lung cancers |
title_short | Decade in review: a new era for RET-rearranged lung cancers |
title_sort | decade in review: a new era for ret-rearranged lung cancers |
topic | Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815364/ https://www.ncbi.nlm.nih.gov/pubmed/33489819 http://dx.doi.org/10.21037/tlcr-20-346 |
work_keys_str_mv | AT choudhurynouraj decadeinreviewaneweraforretrearrangedlungcancers AT drilonalexander decadeinreviewaneweraforretrearrangedlungcancers |